Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
BMIQ9
MCID: BDY005
MIFTS: 47

Body Mass Index Quantitative Trait Locus 9 (BMIQ9)

Categories: Bone diseases, Genetic diseases, Mental diseases, Metabolic diseases
Genes Variations Tissues Related diseases Publications Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Body Mass Index Quantitative Trait Locus 9

About this section

MalaCards integrated aliases for Body Mass Index Quantitative Trait Locus 9:

Name: Body Mass Index Quantitative Trait Locus 9 57 29 6 39
Obesity, Severe, Susceptibility to, Bmiq9 57 13
Obesity 57 71
Obesity, Susceptibility to 57
Obesity, Severe Bmiq9 57
Bmiq9 57

Characteristics:

OMIM®:

57 (Updated 05-Mar-2021)
Inheritance:
broad locus on 20q


Classifications:

MalaCards categories:
Global: Genetic diseases Metabolic diseases
Anatomical: Bone diseases Mental diseases
See all MalaCards categories (disease lists)


External Ids:

OMIM® 57 602025
MedGen 41 C2677162
SNOMED-CT via HPO 68 414915002 414916001
UMLS 71 C0028754
Sources

Summaries for Body Mass Index Quantitative Trait Locus 9

About this section
MalaCards based summary : Body Mass Index Quantitative Trait Locus 9, also known as obesity, severe, susceptibility to, bmiq9, is related to body mass index quantitative trait locus 11 and body mass index quantitative trait locus 19, and has symptoms including symptoms, high weight and obesity, metabolically benign. An important gene associated with Body Mass Index Quantitative Trait Locus 9 is MC3R (Melanocortin 3 Receptor). The drugs Dalteparin and Clarithromycin have been mentioned in the context of this disorder. Affiliated tissues include liver, bone and endothelial, and related phenotype is obesity.

More information from OMIM: 602025
Sources

Related Diseases for Body Mass Index Quantitative Trait Locus 9

About this section

Diseases in the Body Mass Index Quantitative Trait Locus 11 family:

Body Mass Index Quantitative Trait Locus 9 Body Mass Index Quantitative Trait Locus 8
Body Mass Index Quantitative Trait Locus 1 Body Mass Index Quantitative Trait Locus 2
Body Mass Index Quantitative Trait Locus 3 Body Mass Index Quantitative Trait Locus 4
Body Mass Index Quantitative Trait Locus 10 Body Mass Index Quantitative Trait Locus 7
Body Mass Index Quantitative Trait Locus 5 Body Mass Index Quantitative Trait Locus 6
Body Mass Index Quantitative Trait Locus 12 Body Mass Index Quantitative Trait Locus 13
Body Mass Index Quantitative Trait Locus 14 Body Mass Index Quantitative Trait Locus 15
Body Mass Index Quantitative Trait Locus 18 Body Mass Index Quantitative Trait Locus 19
Body Mass Index Quantitative Trait Locus 20

Diseases related to Body Mass Index Quantitative Trait Locus 9 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1911)
# Related Disease Score Top Affiliating Genes
1 body mass index quantitative trait locus 11 12.0
2 body mass index quantitative trait locus 19 11.9
3 leptin deficiency or dysfunction 11.8
4 body mass index quantitative trait locus 4 11.8
5 body mass index quantitative trait locus 12 11.8
6 body mass index quantitative trait locus 8 11.8
7 body mass index quantitative trait locus 7 11.8
8 body mass index quantitative trait locus 18 11.8
9 body mass index quantitative trait locus 14 11.8
10 body mass index quantitative trait locus 10 11.8
11 leptin receptor deficiency 11.5
12 cohen syndrome 11.5
13 obesity-hypoventilation syndrome 11.5
14 obesity, early-onset, with adrenal insufficiency and red hair 11.5
15 wilson-turner x-linked mental retardation syndrome 11.5
16 abdominal obesity-metabolic syndrome 3 11.5
17 mehmo syndrome 11.5
18 morbid obesity and spermatogenic failure 11.5
19 abdominal obesity-metabolic syndrome quantitative trait locus 2 11.5
20 proprotein convertase 1/3 deficiency 11.4
21 abdominal obesity-metabolic syndrome 1 11.4
22 mental retardation, truncal obesity, retinal dystrophy, and micropenis syndrome 11.4
23 obesity, hyperphagia, and developmental delay 11.4
24 abdominal obesity-metabolic syndrome 4 11.4
25 hypothalamic obesity 11.4
26 spastic paraplegia, intellectual disability, nystagmus, and obesity 11.4
27 momo syndrome 11.4
28 retinal dystrophy and obesity 11.4
29 chung-jansen syndrome 11.4
30 chops syndrome 11.4
31 genetic obesity 11.3
32 wilms tumor, aniridia, genitourinary anomalies, mental retardation, and obesity syndrome 11.3
33 body mass index quantitative trait locus 20 11.3
34 fatty liver disease 11.3
35 non-alcoholic fatty liver disease 11.3
36 hydrocephalus obesity hypogonadism 11.3
37 ayazi syndrome 11.3
38 rohhad 11.2
39 coenzyme q10 deficiency, primary, 2 11.2
40 x-linked intellectual disability - short stature - obesity 11.2
41 aniridia - ptosis - intellectual disability - familial obesity 11.2
42 type 2 diabetes mellitus 11.2
43 prader-willi syndrome 11.2
44 glucose intolerance 11.2
45 body mass index quantitative trait locus 1 11.2
46 polycystic ovary syndrome 11.2
47 eating disorder 11.2
48 alstrom syndrome 11.2
49 man1b1-cdg 11.1
50 carpenter syndrome 1 11.1

Graphical network of the top 20 diseases related to Body Mass Index Quantitative Trait Locus 9:



Diseases related to Body Mass Index Quantitative Trait Locus 9
Sources

Symptoms & Phenotypes for Body Mass Index Quantitative Trait Locus 9

About this section

Human phenotypes related to Body Mass Index Quantitative Trait Locus 9:

31
# Description HPO Frequency HPO Source Accession
1 obesity 31 HP:0001513

Symptoms via clinical synopsis from OMIM®:

57 (Updated 05-Mar-2021)
Growth:
body fat content

Lab:
fasting insulin levels

Clinical features from OMIM®:

602025 (Updated 05-Mar-2021)

UMLS symptoms related to Body Mass Index Quantitative Trait Locus 9:


symptoms, high weight, obesity, metabolically benign, monogenic obesity
Sources

Drugs & Therapeutics for Body Mass Index Quantitative Trait Locus 9

About this section

Drugs for Body Mass Index Quantitative Trait Locus 9 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 944)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dalteparin Approved Phase 4 9005-49-6
2
Clarithromycin Approved Phase 4 81103-11-9 84029
3
Bismuth subsalicylate Approved, Vet_approved Phase 4 14882-18-9 53629521
4
Clopidogrel Approved Phase 4 120202-66-6, 113665-84-2 60606
5
Ticagrelor Approved Phase 4 274693-27-5 9871419
6
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
7
Dexlansoprazole Approved, Investigational Phase 4 138530-94-6, 103577-45-3 9578005
8
Lansoprazole Approved, Investigational Phase 4 103577-45-3 3883
9
Linagliptin Approved Phase 4 668270-12-0 10096344
10
Indapamide Approved Phase 4 26807-65-8 3702
11
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
12
Linezolid Approved, Investigational Phase 4 165800-03-3 441401
13
Metyrapone Approved, Investigational Phase 4 54-36-4 4174
14
Tolnaftate Approved, Investigational, Vet_approved Phase 4 2398-96-1 5510
15
Orlistat Approved, Investigational Phase 4 96829-58-2 3034010
16
Zonisamide Approved, Investigational Phase 4 68291-97-4 5734
17
Chlorhexidine Approved, Vet_approved Phase 4 55-56-1 9552079 2713
18
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
19
Ziprasidone Approved Phase 4 146939-27-7 60854
20
Magnesium oxide Approved Phase 4 1309-48-4 14792
21
Atorvastatin Approved Phase 4 134523-00-5 60823
22
Fenofibrate Approved Phase 4 49562-28-9 3339
23
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
24
Levoleucovorin Approved, Investigational Phase 4 68538-85-2 149436
25
Meropenem Approved, Investigational Phase 4 96036-03-2, 119478-56-7 64778 441130
26
Ertapenem Approved, Investigational Phase 4 153832-46-3 150610
27
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
28
Rosiglitazone Approved, Investigational Phase 4 122320-73-4 77999
29
Calcium carbonate Approved, Investigational Phase 4 471-34-1
30
Olmesartan Approved, Investigational Phase 4 144689-24-7, 144689-63-4 158781 130881
31
Octreotide Approved, Investigational Phase 4 83150-76-9 383414 6400441
32
Tadalafil Approved, Investigational Phase 4 171596-29-5 110635
33
Repaglinide Approved, Investigational Phase 4 135062-02-1 65981
34
Losartan Approved Phase 4 114798-26-4 3961
35
Coal tar Approved Phase 4 8007-45-2
36
Ofloxacin Approved Phase 4 82419-36-1 4583
37
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
38
Bazedoxifene Approved, Investigational Phase 4 198481-32-2
39
Micafungin Approved, Investigational Phase 4 235114-32-6 3081921 477468
40
Tedizolid Approved, Investigational Phase 4 856866-72-3
41
Tedizolid phosphate Approved Phase 4 856867-55-5
42
Posaconazole Approved, Investigational, Vet_approved Phase 4 171228-49-2 147912
43
Cyclophosphamide Approved, Investigational Phase 4 50-18-0, 6055-19-2 2907
44
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
45
Efavirenz Approved, Investigational Phase 4 154598-52-4 64139
46
Doxorubicin Approved, Investigational Phase 4 23214-92-8 31703
47
Lactitol Approved, Investigational Phase 4 585-86-4 157355
48
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
49
Parathyroid hormone Approved, Investigational Phase 4 9002-64-6
50
Memantine Approved, Investigational Phase 4 19982-08-2 4054

Interventional clinical trials:

(show top 50) (show all 7730)
# Name Status NCT ID Phase Drugs
1 Vitamin D Concentrations and Their Effect on Glucose Metabolism in Pediatrics Unknown status NCT01386736 Phase 4 Vitamin D drops;Placebo drops
2 Comparing the Efficacy of Two Frequently Used Doses of Enoxaparin for VTE Prophylaxis After Bariatric Surgery Unknown status NCT01970202 Phase 4 40mg Enoxaparin;60mg Enoxaparin
3 The Effect of Obesity in Dexmedetomidine Metabolic Clearance Unknown status NCT02557867 Phase 4 Dexmedetomidine
4 The Effect of Vitamin A Supplementation on CD4+ T-cell Secretion in Obese Individuals Unknown status NCT01405352 Phase 4
5 Weight Reduction Alone May Not be Sufficient to Maintain Disease Remission in Obese Patients With Psoriasis: a Randomized, Investigator-blinded Study Unknown status NCT01439425 Phase 4
6 International, Multi Centre, Open, Prospective, Randomized Study: Banded Versus Conventional Laparoscopic Roux-en-Y (GABY) Unknown status NCT01015469 Phase 4
7 Study of the Concentrations of Long Acting Morphine After Oral Absorption in Subjects Who Underwent Gastric Bypass (OBEMO 2) Unknown status NCT02641301 Phase 4 Sustained release morphine sulfate, 30 mg
8 Levonorgestrel-releasing Intrauterine Device Effects on Hemostatic and Arterial Function of Obese Women Unknown status NCT01320917 Phase 4
9 THE EFFECT OF HELICOBACTER PYLORI ERADICATION THERAPY TO GASTRIC WALL THICKNESS BEFORE THE LAPAROSCOPIC SLEEVE GASTRECTOMY Unknown status NCT03757650 Phase 4 Bismuth Subsalicylate
10 Double-blind Randomized Trial Using Oral Metformin Versus Placebo in the Treatment of Acanthosis Nigricans in Children With Obesity Unknown status NCT02438020 Phase 4 Metformin
11 Evaluation of the Effects of Laying Early (Between 12 and 16) a Gastric Band on the Prevention of Morbid Obesity in Late Adolescence. Randomized Checked Against Standard Management of Obesity in This Population. Unknown status NCT01700738 Phase 4
12 PRotective Effect on the Coronary Microcirculation of Patients With DIabetes by Clopidogrel or Ticagrelor Unknown status NCT02698618 Phase 4 Randomization
13 Early Detection of Atherosclerosis in the Primary Care Setting: a Randomized Trial to Assess the Efficacy of a Novel Strategy in the Primary Prevention of Cardiovascular Diseases. Unknown status NCT00734123 Phase 4 Simvastatin or Atorvastatin;Enalapril;Aspirin or clopidogrel;Rimonabant
14 Effect of aSpirin Versus CilOstazol for Inhibition of Antiplatelet aggRegaTion in Type 2 DM Patients Unknown status NCT02933788 Phase 4 Cilostazol;Acetylsalicylic acid
15 The Effect of Moxonidine and Regression of Early Target Organ Damage in Young Subjects With Abdominal Obesity and Hypertension: a Randomised, Double Blind, Active Comparator Clinical Trial Unknown status NCT01360710 Phase 4 Moxonidine;Irbesartan
16 Prevention and Control of Obesity in Primary School Children in Tehran Unknown status NCT02082080 Phase 4
17 A Study of the Pharmacokinetics of Dexmedetomidine in Morbid Obesity. Unknown status NCT01864187 Phase 4 Dexmedetomidine
18 Comparing Dexlansoprazole With Double-dose Lansoprazole to Achieve Sustained Symptomatic Response in Overweight and Obesity Patients With Reflux Esophagitis in Los Angeles Grades A & B Unknown status NCT02759393 Phase 4 Dexlansoprazole;Lansoprazole
19 Assessment of the Effect of Moxonidine and Diet on Cardiac, Renal and Endothelial Function in Young Subjects With Abdominal Obesity Unknown status NCT01180231 Phase 4 Moxonidine (Physiotens)
20 Double Blinded Randomised Trial Comparing Metformin Versus Placebo in NASH Patients Receiving Bariatric Surgery for Obesity Unknown status NCT00134303 Phase 4 Metformin
21 Effect of Saxagliptin on Body Fat , Glucose and Beta Cell Function in Patients With Newly Diagnosed Pre-Diabetes Mellitus and Obesity Unknown status NCT01960205 Phase 4 Saxagliptin;saxagliptin;metformin
22 The Therapeutic Effect of Catgut Embedding in Obesity-A Randomized, Double-blind, Placebo-controlled Clinical Trial Unknown status NCT02276235 Phase 4
23 Effect of Acarbose and Vildagliptin on Visceral Fat Distribution in Overweight and Obesity Patients With Newly Diagnosed Type 2 Diabetes Mellitus: A Randomized Control Study Unknown status NCT02999841 Phase 4 Acarbose;Vildagliptin
24 Healthy Opportunities for Physical Activity and Nutrition (HOP'N) After-School Project Unknown status NCT01015599 Phase 4
25 Laparoscopic Non Banded Vertical (Magenstrasse and Mill) Gastroplasty In Bariatric Surgery. Morbidity and Results on Weight Loss and Associated Co-morbidities Unknown status NCT02050477 Phase 4
26 Laparoscopic Roux-en-Y Gastric Bypass vs. Laparoscopic BPD-Duodenal Switch for Superobesity (BMI > 50 kg/m2)- A Randomized Clinical Trial Unknown status NCT00327912 Phase 4
27 Endobarrier Treatment in Obese Subjects With T2DM Unknown status NCT01718457 Phase 4
28 Correlation of Postoperative VAS Values and Body Mass Index in Patients Undergoing Abdominal Surgery: A Clinical Trial Unknown status NCT02017314 Phase 4 Morphine
29 Laparoscopic Bariatric Surgery: Impact of the Level of Neuromuscular Blockade on Surgical Conditions - Comparison Between Moderate and Deep Neuromuscular Blockade Unknown status NCT02118844 Phase 4 rocuronium
30 Prospective Randomized Study of Effects of Laparoscopic Roux-en-Y Gastric Bypass Versus Laparoscopic Sleeve Gastrectomy Unknown status NCT00667706 Phase 4
31 Prospective, Pharmacokinetic Study for Determination of the Relationship Between Lean Body Weight and Anti-Xa Activity 4 Hours After Subcutaneous Injection of 5700 IU Nadroparin in Morbidly Obese Patients After Bariatric Surgery. Unknown status NCT02295150 Phase 4 Nadroparin
32 Gut Hormones as Mediators of Different Weight Loss Responses After Roux-en-Y Gastric Bypass Unknown status NCT02374632 Phase 4
33 Influence of the Aromatase Inhibitor Letrozole on Heart and Liver Function in Obese Men Unknown status NCT02097680 Phase 4 Letrozole;Placebo
34 HYpertension Therapy With Valsartan Versus EpleRenone for Obese Patients: A Randomized Clinical Trial Unknown status NCT03476616 Phase 4 Eplerenone (-based therapy) arm;Valsartan (-based therapy) arm
35 Evaluation of Family Intervention Program for the Treatment of Overweight or Obese Children (Nereu Program): Randomized Clinical Trial Unknown status NCT01878994 Phase 4
36 Study of Metabolic Effects of EndoBarrier Versus Intragastric Balloon in Obese Patients With Type 2 Diabetes. Unknown status NCT01848795 Phase 4
37 The Need of Dosing Adjustment for Simvastatin in Obese Patients Post Bariatric Surgery- Laparoscopic Sleeve Gastrectomy (LSG) Unknown status NCT03571802 Phase 4 Simvastatin
38 Heparin Management for Cardiopulmonary Bypass in Cardiac Surgery: A Prospective, Comparative and Randomized Study Evaluating a Dosage Based on the Ideal Body Weight in Obese Patients Unknown status NCT02675647 Phase 4 Heparin, IV route, based on patients body weights (UI/kg);Protamin administration
39 Effects of GLP-1 Receptor Agonist Treatment on Pulmonary Function and Quality of Life in Obese Patients With Chronic Obstructive Pulmonary Disease. Unknown status NCT03466021 Phase 4 Liraglutide;Placebo
40 Pharmacokinetic and Pharmacodynamic Evaluation of Linezolid Administered Intravenously in MRSA-positive, Morbidly Obese Patients With Pneumonia Unknown status NCT01805284 Phase 4 Linezolid
41 What is the Effects of Incretin on the Blood Pressure and Lipid in Overweight or Obese Diabetes Patients With Masked Hypertension: Liraglutide Plus Mitiglinide Comparing Metformin Plus Mitiglinide or Mitiglinide Alone（BLOOD STUDY） Unknown status NCT02503943 Phase 4 "Liraglutide" and "Mitiglinide";"Metformin" and "Mitiglinide";"Mitiglinide"
42 Ultrasonographic Modification of Liver Steatosis and Visceral Fat Induced by Treatment With Losartan and Simvastatin in Hypertensive Normocholesterolemic Obese Patients Unknown status NCT00669435 Phase 4 Losartan + Simvastatin;Amlodipine + Simvastatin
43 Structured Exerise Training in Infertile Obese Patients Treated With Assisted Reproductive Techniques: a Randomized Controlled Trial Unknown status NCT01892111 Phase 4
44 The Effects of Cortisol Blockade on Nutritional Sympathetic Nervous System Responsiveness in Overweight and Obese Subjects With Metabolic Syndrome Unknown status NCT01620684 Phase 4 metyrapone;placebo
45 Combined Effects of SGLT2 Inhibition and GLP-1 Receptor Agonism on Food Intake, Body Weight and Central Satiety and Reward Circuits in Obese T2DM Patients Unknown status NCT03361098 Phase 4 Dapagliflozin 10mg;Exenatide
46 Retroclavicular Approach vs Infraclavicular Approach for Brachial Plexus Block in Obese Unknown status NCT02990702 Phase 4 Bupivacaine
47 Oral Tramadol Versus Oral Celecoxib for Post-perineal Repair Analgesia After Spontaneous Vaginal Birth in Obese Women: A Randomised Controlled Trial Unknown status NCT03694873 Phase 4 Tramadol Hydrochloride;Celecoxib 200mg
48 The Effect of TRADJENTA ® (LINAGLIPTIN) on Inflammation, Oxidative Stress and Insulin Resistance in Obese Type 2 Diabetes Subjects Unknown status NCT02372630 Phase 4 Linagliptin;Placebo
49 Double-blind and Placebo-controlled Study on Intervention Effect of n-3 Fatty Acids on Glucose and Lipid Homeostasis Disorders in Obese/Diabetic Populations Unknown status NCT03708887 Phase 4 Low dose omega-3 fatty acid supplementation;High dose omega-3 fatty acid supplementation;Control drug
50 The Use of Antimicrobial Gauze in Pregnant Women Undergoing C-section With BMI >40 to Decrease Wound Complications by 6 Weeks postpartum--a Small Feasibility Study Unknown status NCT02882360 Phase 4

Search NIH Clinical Center for Body Mass Index Quantitative Trait Locus 9

Inferred drug relations via UMLS 71 / NDF-RT 51 :


Benzphetamine
Benzphetamine hydrochloride
Dexfenfluramine
Dexfenfluramine Hydrochloride
Diethylpropion
Diethylpropion Hydrochloride
Fenfluramine
Fenfluramine Hydrochloride
lorcaserin
lorcaserin hydrochloride
Mazindol
Methamphetamine
orlistat
phendimetrazine
PHENDIMETRAZINE HYDROCHLORIDE
phendimetrazine tartrate
Phenmetrazine
Phenmetrazine Hydrochloride
Phentermine
Phentermine Hydrochloride
PHENTERMINE RESIN
Phenylpropanolamine
Phenylpropanolamine Hydrochloride
sibutramine
SIBUTRAMINE HYDROCHLORIDE
Sources

Genetic Tests for Body Mass Index Quantitative Trait Locus 9

About this section

Genetic tests related to Body Mass Index Quantitative Trait Locus 9:

# Genetic test Affiliating Genes
1 Body Mass Index Quantitative Trait Locus 9 29 MC3R
Sources

Anatomical Context for Body Mass Index Quantitative Trait Locus 9

About this section

MalaCards organs/tissues related to Body Mass Index Quantitative Trait Locus 9:

40
Liver, Bone, Endothelial, Heart, Breast, Brain, Ovary
Sources

Publications for Body Mass Index Quantitative Trait Locus 9

About this section

Articles related to Body Mass Index Quantitative Trait Locus 9:

(show top 50) (show all 30011)
# Title Authors PMID Year
1
Rare melanocortin-3 receptor mutations with in vitro functional consequences are associated with human obesity. 6 57
21047972 2011
2
Sporadic mutations in melanocortin receptor 3 in morbid obese individuals. 57 6
18231126 2008
3
Functional characterization of melanocortin-3 receptor variants identify a loss-of-function mutation involving an amino acid critical for G protein-coupled receptor activation. 6 57
15292330 2004
4
A novel melanocortin 3 receptor gene (MC3R) mutation associated with severe obesity. 57 6
11889220 2002
5
Co-occurrence of two partially inactivating polymorphisms of MC3R is associated with pediatric-onset obesity. 57 61
16123355 2005
6
Association of functionally significant Melanocortin-4 but not Melanocortin-3 receptor mutations with severe adult obesity in a large North American case-control study. 57
19091795 2009
7
Inactivation and intracellular retention of the human I183N mutated melanocortin 3 receptor associated with obesity. 6
15276649 2004
8
Interacting genetic loci on chromosomes 20 and 10 influence extreme human obesity. 57
12478478 2003
9
Linkage of body mass index to chromosome 20 in Utah pedigrees. 57
11702208 2001
10
Genome scan for human obesity and linkage to markers in 20q13. 57
9915959 1999
11
Identification of an obesity quantitative trait locus on mouse chromosome 2 and evidence of linkage to body fat and insulin on the human homologous region 20q. 57
9276742 1997
12
Methods for the study of histocompatibility genes. 57
18893744 1948
13
Blood pro-oxidant/antioxidant balance in young men with class II obesity after 20 sessions of whole body cryostimulation: a preliminary study. 61
33560197 2021
14
Brown and beige adipose tissue: a novel therapeutic strategy for obesity and type 2 diabetes mellitus. 61
33403891 2021
15
The role and research progress of the balance and interaction between regulatory T cells and other immune cells in obesity with insulin resistance. 61
33472506 2021
16
Association between rs174537 FADS1 polymorphism and immune cell profiles in abdominal and femoral subcutaneous adipose tissue: an exploratory study in adults with obesity. 61
33595419 2021
17
Polysaccharide fraction from greens of Raphanus sativus alleviates high fat diet-induced obesity. 61
33268179 2021
18
A novel and disposable GP- based impedimetric biosensor using electropolymerization process with PGA for highly sensitive determination of leptin: Early diagnosis of childhood obesity. 61
33592733 2021
19
The association between the level of serum 25(OH) vitamin D, obesity, and underlying diseases with the risk of developing COVID-19 infection: A case-control study of hospitalized patients in Tehran, Iran. 61
33314166 2021
20
Hepatic Ago2 Regulates PPARα for Oxidative Metabolism Linked to Glycemic Control in Obesity and Post Bariatric Surgery. 61
33567453 2021
21
Food addiction, executive function and mood in adolescents with obesity seeking treatment. 61
33227386 2021
22
The Relationship between Sleep, Obesity, and Metabolic Health in Adolescents - a Review. 61
33283071 2021
23
Beinaglutide shows significantly beneficial effects in diabetes/obesity-induced nonalcoholic steatohepatitis in ob/ob mouse model. 61
33482185 2021
24
Long non-coding RNA Meg3 deficiency impairs glucose homeostasis and insulin signaling by inducing cellular senescence of hepatic endothelium in obesity. 61
33508742 2021
25
The effect of restrained eating on acute stress-induced food intake in people with obesity. 61
33227382 2021
26
PFAS exposure and overweight/obesity among children in a nationally representative sample. 61
33223205 2021
27
Plants used against obesity in Turkish folk medicine: A review. 61
33460757 2021
28
Circulating adipokine concentrations and risk of five obesity-related cancers: A Mendelian randomization study. 61
33038280 2021
29
Sleep Duration, Sleep Timing, and Sleep Disordered Breathing-Associations With Obesity and Gestational Diabetes in Pregnancy. 61
33481418 2021
30
Identification of a novel leptin receptor (LEPR) variant and proof of functional relevance directing treatment decisions in patients with morbid obesity. 61
33221380 2021
31
LKB1 up-regulation inhibits hypothalamic inflammation and attenuates diet-induced obesity in mice. 61
33358943 2021
32
Correction to: An Exploration of the Role of Sugar-Sweetened Beverage in Promoting Obesity and Health Disparities. 61
33528795 2021
33
Adiposity and cardiovascular outcomes in three-year-old children of participants in UPBEAT, an RCT of a complex intervention in pregnant women with obesity. 61
32914569 2021
34
Association of organic food consumption with obesity in a nationally representative sample. 61
32799959 2021
35
Maternal and paternal obesity are associated with offspring obestatin levels in the Nutritionists' Health Study. 61
33348107 2021
36
Maternal obesity is associated with phenotypic alterations in fetal immune cells by single-cell mass cytometry. 61
33064324 2021
37
GWA-based pleiotropic analysis identified potential SNPs and genes related to type 2 diabetes and obesity. 61
32948839 2021
38
Prevalence and Effect of Obesity on Mobility According to Different Criteria in Polio Survivors. 61
33595937 2021
39
Dopamine D2/3 receptor availability in cocaine use disorder individuals with obesity as measured by [11C]PHNO PET. 61
33454626 2021
40
Journal of Nutritional Biochemistry Special Issue: Polyphenols, obesity, and cardiometabolic health. 61
33321186 2021
41
Sleep apnea, obesity and COPD depress respiration during catheter ablation procedures: Implications for transcutaneous carbon dioxide monitoring. 61
33152419 2021
42
Prevalence of elevated liver enzymes and comorbidities in children and adolescents with overweight and obesity. 61
32649794 2021
43
Clearing Up the Obesity Paradox in Cardiac Surgery. 61
32660926 2021
44
Retraction notice to "Placental serotonin systems in pregnancy metabolic complications associated with maternal obesity and gestational diabetes mellitus." [Biochim. Biophys. Acta (BBA) - Mol. Basis Dis. 1866 (2020) 65391]. 61
33384199 2021
45
Obesity-induced upregulation of microRNA-183-5p promotes hepatic triglyceride accumulation by targeting the B-cell translocation gene 1. 61
33421522 2021
46
Skeletal muscle non-shivering thermogenesis as an attractive strategy to combat obesity. 61
33450257 2021
47
Are we overdiagnosing obesity in preschool children? 61
32444449 2021
48
Impact of Obesity on Measures of Cardiovascular and Kidney Health in Youth With Type 1 Diabetes as Compared With Youth With Type 2 Diabetes. 61
33402367 2021
49
Clinical Assessment and Treatment of Early-Onset Severe Obesity. 61
33411312 2021
50
Reducing intergenerational obesity and diabetes risk. 61
33404682 2021
Sources

Variations for Body Mass Index Quantitative Trait Locus 9

About this section

ClinVar genetic disease variations for Body Mass Index Quantitative Trait Locus 9:

6
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 MC3R NM_019888.3(MC3R):c.437T>A (p.Ile146Asn) SNV risk factor 14339 rs74315393 20:54824336-54824336 20:56249280-56249280
2 MC3R NM_019888.3(MC3R):c.893T>G (p.Ile298Ser) SNV risk factor 14340 rs121913556 20:54824792-54824792 20:56249736-56249736
Sources

Expression for Body Mass Index Quantitative Trait Locus 9

About this section
Search GEO for disease gene expression data for Body Mass Index Quantitative Trait Locus 9.
Sources

Pathways for Body Mass Index Quantitative Trait Locus 9

About this section
Sources

GO Terms for Body Mass Index Quantitative Trait Locus 9

About this section
Sources

Sources for Body Mass Index Quantitative Trait Locus 9

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....